Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Dolutegravir/Lamivudine FDC in Healthy Subjects
NCT02738931Phase 1Completed
- Sponsor
- ViiV Healthcare
- Start
- May 2016
- Primary completion
- Jun 2016
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dolutegravir + lamivudine in human immunodeficiency virus type 1 infection (HIV-1) (6 arms), sponsored by ViiV Healthcare. Primary endpoints: Dolutegravir Area Under the Concentration-Time Curve from Time 0 Extrapolated to Infinity at 48 hours, Dolutegravir Maximum Observed Concentration at 48 hours and 2 more. Started May 2016; status: completed.
02
Drugs
dolutegravir + lamivudine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02738931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02738931.